Abstract
Pancreatic islet transplantation into the liver provides a possibility to treat selected patients with brittle type 1 diabetes mellitus. However, massive early β-cell death increases the number of islets needed to restore glucose homeostasis. Moreover, late dysfunction and death contribute to the poor long-term results of islet transplantation on insulin independence. Studies in recent years have identified early and late challenges for transplanted pancreatic islets, including an instant blood-mediated inflammatory reaction when exposing human islets to the blood microenvironment in the portal vein and the low oxygenated milieu of islets transplanted into the liver. Poor revascularization of remaining intact islets combined with severe changes in the gene expression of islets transplanted into the liver contributes to late dysfunction. Strategies to overcome these hurdles have been developed, and some of these interventions are now even tested in clinical trials providing a hope to improve results in clinical islet transplantation. In parallel, experimental and clinical studies have, based on the identified problems with the liver site, evaluated the possibility of change of implantation organ in order to improve the results. Site-specific differences clearly exist in the engraftment of transplanted islets, and a more thorough characterization of alternative locations is needed. New strategies with modifications of islet microenvironment with cells and growth factors adhered to the islet surface or in a surrounding matrix could be designed to intervene with site-specific hurdles and provide possibilities to improve future results of islet transplantation.
Highlights
Pancreatic islet transplantation into the liver provides a possibility to treat selected patients with brittle type 1 diabetes mellitus
The intravascular injection of pancreatic islets has been shown to elicit an instant blood-mediated inflammatory reaction (IBMIR) triggered by tissue factor and cyto/ chemokines expressed by pancreatic islets in the whole blood microenvironment of the portal vein [6,7]
This so-called IBMIR occurs in clinical islet transplantation as shown by an increase in concentrations of thrombin–antithrombin complex immediately after islet infusion, and the parallel increase in c-peptide release indicates massive bcell death [7]
Summary
PER-OLA CARLSSON Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden, and Department of Medical Sciences, Uppsala University, Uppsala, Sweden. Fernström Award for young investigators, 2010 at the Medical Faculty of Uppsala University
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.